Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

...

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

...

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

...

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

...

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

...

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

...

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

...

menu
menu